Global Giant-Cell Arteritis Market Trends and Growth Analysis 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Giant-Cell Arteritis Market Over The Five-Year Period 2025–2029?

The giant-cell arteritis market has experienced robust expansion over recent years. It is anticipated to increase from $1.07 billion in 2024 to $1.12 billion in 2025, showing a compound annual growth rate (CAGR) of 5.0%. Historically, this expansion can be ascribed to elements such as epidemiological studies, genetic insights, the increasing uptake of biologics, enhanced diagnostic techniques, and the progression of targeted therapies and biologics.

The giant-cell arteritis market size is expected to experience steady expansion in the upcoming years. It is projected to reach $1.34 billion in 2029, with a compound annual growth rate (CAGR) of 4.6%. This increase during the forecast period is attributable to factors like rising diagnosis rates, an aging population, increasing healthcare expenditure, enhanced patient advocacy, and market expansion into new geographic regions. Significant trends anticipated for the forecast period include progress in biomarker identification and validation, the development of treatments targeting specific molecular pathways, the adoption of advanced imaging techniques, innovations in drug delivery, and the use of AI algorithms for predictive analytics.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

Which Drivers Are Supporting Growth Of The Giant-Cell Arteritis Market?

An increasing focus on personalized medicine is anticipated to drive the expansion of the giant-cell arteritis market moving forward. Personalized medicine involves customizing medical care to match individual characteristics, such as genetics, lifestyle, and environmental factors. The adoption of personalized medicine is growing due to advancements in genomics, biotechnology, and data analytics, which facilitate targeted therapies that enhance treatment effectiveness and minimize adverse reactions for individuals. In the context of giant-cell arteritis (GCA), personalized medicine offers the potential for tailored treatments based on unique patient factors like genetic predispositions, immune profiles, and specific disease manifestations. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit organization, reported that personalized medicines comprised over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023. During that year, the FDA approved 16 new personalized treatments specifically for rare diseases, representing a significant increase from six approvals recorded in 2022. Furthermore, the approvals in 2023 included seven cancer medications and three treatments for various other diseases and conditions. Therefore, the heightened emphasis on personalized medicine is fueling the growth of the giant-cell arteritis market.

Which Key Segments Fueling The Giant-Cell Arteritis Market?

The giant-cell arteritismarket covered in this report is segmented –

1) By Therapeutics: Prednisone; Methotrexate; Tocilizumab; Aspirin

2) By Mechanism Of Action: Corticosteroids; Immunosuppressive Agents; Anticoagulants; Other Mechanisms Of Action

3) By Route Of Administration: Oral; Intravenous; Subcutaneous; Other Routes Of Administration

Subsegments:

1) By Prednisone: Oral Prednisone; Intravenous (IV) Prednisone; Low-Dose Prednisone Therapy; High-Dose Prednisone Therapy

2) By Methotrexate: Oral Methotrexate; Subcutaneous Methotrexate; Methotrexate Monotherapy; Methotrexate Combination Therapy

3) By Tocilizumab: Intravenous Tocilizumab; Subcutaneous Tocilizumab; Tocilizumab Monotherapy; Tocilizumab In Combination With Corticosteroids

4) By Aspirin: Low-Dose Aspirin Therapy; Aspirin For Cardiovascular Risk Management; Aspirin In Combination Therapy; Enteric-Coated Aspirin

Which Competitive Trends Are Defining The Giant-Cell Arteritis Market Structure?

Leading companies engaged in the giant-cell arteritis sector are developing novel products, including biosimilars, to expand treatment possibilities and address patients’ unmet medical needs. A biosimilar is defined as a biological drug that is remarkably similar to an already approved biological product, showing no clinically significant disparities in terms of safety, purity, and potency. For example, in April 2024, Fresenius SE & Co. KGaA, a healthcare company based in Germany, introduced Tocilizumab-aazg in the US for the treatment of chronic autoimmune diseases. This biosimilar has received approval for conditions such as rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval was founded on data from a randomized, double-blind, single-dose, parallel phase 1 trial that compared its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab across three patient cohorts.

Which Leading Companies Dominate The Giant-Cell Arteritis Market Share?

Major companies operating in the giant-cell arteritis market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Limited, Kiniksa Pharmaceuticals Ltd., MorphoSys AG

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

How Do Regional Market Performances Compare Within The Giant-Cell Arteritis Industry?

North America was the largest region in the giant-cell arteritis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Giant-Cell Arteritis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2025, By The Business Research Company

Cell Culture Consumables And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-culture-consumables-and-equipment-global-market-report

Stem Cell Cord Blood Banking Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report

Induced Pluripotent Stem Cell Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/induced-pluripotent-stem-cell-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795